Which biomarker to use, when to start, and how to improve adherence for reducing atherosclerotic cardiovascular disease risk?

This commentary refers to ‘2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease’, by M.B. Mortensen and B.G. Nordestgaard, doi:10.1093/eurheartj/ehaa150 and the discussion piece ‘Examine low-density lipoprotein, remnants, and lipoprotein(a) in parallel in high risk pa tients’, by M.B. Mortensen and B.G. Nordestgaard, doi:10.1093/eurheartj/ehaa969.
Source: European Heart Journal - Category: Cardiology Source Type: research